3 results
Approved WMOCompleted
Efficacy and safety during 24 treatment weeks.
Approved WMOCompleted
Primary: To demonstrate non-inferiority of RELVAR 100/25 once-daily to SERETIDE 250/50 twice-daily in adult and adolescent subjects 12 years of age and older with persistent asthma,adequately controlled on twice-daily ICS/LABA. Secondary: Adverse…
Approved WMOCompleted
Primary• To compare the anticholinergic side effects between repeated intravaginal administration of oxybutynin with the vaginal MedRing device and repeated oral administrationSecondary• To explore the pharmacokinetics of oxybutynin and its main…